{
    "title": "115_s1509",
    "content": "The Act titled \"Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017\" extends exclusivity periods for drugs approved for new indications for rare diseases or conditions. The Secretary designates drugs approved for new indications to prevent, diagnose, or treat rare diseases for extension purposes if certain criteria are met. The Secretary designates drugs for new indications to prevent, diagnose, or treat rare diseases if criteria are met. The designation cannot be revoked except in specific circumstances. The Secretary can extend periods for drug approvals for new rare disease indications by 6 months. Public notice is required for drug designations. The Secretary can extend drug approval periods for rare disease indications by 6 months if certain conditions are met, including listed patents and certifications under section 505. The drug approval period can be extended by 6 months if certain conditions are met, including listed patents and certifications under section 505. The drug approval period can be extended by 6 months under certain conditions, in addition to other possible extensions, for drugs designated for rare diseases or conditions. The drug approval period can be extended by 6 months for drugs approved for new indications for rare diseases or conditions, in addition to other possible extensions. The 6-month extensions for drug approval can be granted for new indications for rare diseases or conditions, in addition to other possible extensions under section 505G. The amendment expands the relation to pediatric exclusivity and exclusivity for drugs approved for new indications for rare diseases or conditions. It also includes extensions under sections 505A and 505G for biological products approved for new indications for rare diseases or conditions. The 6-month extensions for exclusivity periods after pediatric exclusivity application are additional to any extensions under section 505G. SEC. 3. ORPHAN DRUGS. Section 527 of the Federal Food, Drug, and Cosmetic Act is amended to specify the approval process for drugs that are the same as already approved drugs during a 7-year period. The amendment to Section 527 of the Federal Food, Drug, and Cosmetic Act outlines the approval process for drugs that are the same as already approved drugs during a 7-year period. The amendment includes conditions for clinical superiority and changes in the approval process. The Secretary requires sponsors seeking exclusive approval for a drug already approved for a rare disease to demonstrate clinical superiority over existing drugs in terms of efficacy, safety, or patient care. Regulations may be established by the Secretary. The Secretary may establish regulations for the implementation of demonstrating clinical superiority for drugs approved for rare diseases. The Secretary can apply existing definitions until new regulations are promulgated. The Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 requires the publication of a summary of clinical superiority findings when granting exclusive approval based on demonstrating clinical superiority. This does not affect previous determinations under the Federal Food, Drug, and Cosmetic Act. SEC. 4. Pediatric information added to labeling. Section 505A(o) of the Federal Food, Drug, and Cosmetic Act is amended to include provisions related to exclusivity under different sections. The amendment to Section 505A(o) of the Federal Food, Drug, and Cosmetic Act includes provisions regarding exclusivity for pediatric formulations under sections 505 and 527. The amendment to Section 505A(o) of the Federal Food, Drug, and Cosmetic Act addresses eligibility for approval of applications omitting certain conditions entitled to exclusivity under sections 505 and 527."
}